standard dosing cjc-1295 ipamorelin AOD-9604 + + Dosage: 12 mg Blend typical dose cjc-1295 ipamorelin combined

Clinical Evidence HIV patients: 26-week trials show 20% reduction in abdominal fat Metabolic syndrome patients: Improvements in triglycerides, liver fat, and insulin sensitivity Ideal Candidates for Tesamorelin People with visceral obesity Patients with metabolic syndrome or insulin resistance Individuals able to commit to daily injections and lab monitoring Ipamorelin: Gentle Growth Hormone Booster Ipamorelin is a selective ghrelin receptor agonist that stimulates GH without significantly affecting cortisol, prolactin, or ACTH

What makes Ipamorelin different from some other secretagogues, like Sermorelin, is its specific action

A Receptor in Pituitary and Hypothalamus That Functions in Growth Hormone Release

Moreover, IGF-1 LR3s ability to modulate glucose metabolismby restricting glucose transport into cellsencourages the use of fat as an energy source, facilitating significant fat loss